JPMorgan (NYSE:JPM) gave their 2011 outlook on numerous companies within the MedTech sector today, with their favorites being St. Jude (NYSE:STJ), Covidien (NYSE:COV), Insulet (Nasdaq:PODD) and BioMimetic Therapeutics (Nasdaq:BMTI)
Those companies with the sector JPMorgan expects to outperform include Becton, Dickinson and Company (NYSE:BDX), Stryker (NYSE:SYK), Varian Medical (NYSE:VAR), Edwards Lifesciences (NYSE:EW), Nxstage Medical (Nasdaq:NXTM), Hologic (Nasdaq:HOLX), Heartware (Nasdaq:HTWR), Volcano (Nasdaq:VOLC) and SonoSite (Nasdaq:SONO).
MedTech companies viewed with downside by JPMorgan are Intuitive Surgical (Nasdaq:ISRG), Boston Scientific (NYSE:BSX), Medtronic (NYSE:MDT), Wright Medical Group (Nasdaq:WMGI), CareFusion (NYSE:CFN), Thoratec (Nasdaq:THOR) NuVasive (Nasdaq:NUVA), Mako Surgical (Nasdaq:MAKO) and American Medical Systems (Nasdaq:AMMD).
St. Jude closed Tuesday at $42.28, losing $0.47, or 1.10 percent. Covidien closed at $47.45, gaining $1.79, or 3.92 percent. Insulet ended the day at $16.07, up $0.57, or 3.68 percent. BioMimetic Therapeutics closed at $13.46, up $0.76, or 5.98 percent.
No comments:
Post a Comment